FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3127161133> ?p ?o ?g. }

• W3127161133 endingPage "163" @default.
• W3127161133 startingPage "149" @default.
• W3127161133 abstract "The goal of this article is to review the clinical pharmacology, pharmacokinetics, efficacy, and safety of lemafulin. We performed a systematic literature review using the search terms of lefamulin and BC-3781 in the PubMed and EMBASE databases. We also cross-referenced the pertinent articles and searched ClinicalTrials.gov to identify ongoing and nonpublished studies. Published data from 2005 to 2019 evaluating the clinical pharmacology, efficacy, and safety studies of lefamulin were analyzed. In phase 3 clinical trials, two multicenter, randomized double-blinded studies—Lefamulin Evaluation Against Pneumonia 1 and 2 (LEAP 1 and 2)—compared the efficacy and safety of lemafulin with moxifloxacin in patients diagnosed with community-acquired bacterial pneumonia (CABP). Lemafulin given in doses of 600 mg orally or 150 mg intravenously were reported to have comparable efficacy to those of moxifloxacin with or without linezolid in patients with CABP. After the trial, the lefamulin group had an early clinical response (ECR) of 87.3% and the moxifloxacin group had an ECR of 90.2%. The difference of − 2.9% in the ECR was non-significant (CI − 8.5, 2.8). Lemafulin exhibits a unique binding property; therefore, it possess a potentially lower predisposition for the development of bacterial resistance and cross-resistance to other antimicrobial classes. Lefamulin is active against gram-positive including methicillin-resistant strains and atypical organisms which are often implicated in CABP. Lefamulin may be a safe alternative for adult patients with CABP who may not be candidates for respiratory fluoroquinolones. Lefamulin demonstrates both bactericidal and bacteriostatic activity against gram-positive, fastidious gram-negatives, atypical pathogens, and some gram-negative anaerobes. It is bactericidal in vitro against Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae (including macrolide-resistant strains) at concentrations of 0.06, 0.5, and 0.008 µg/ml respectively, and bacteriostatic against Staphylococcus aureus and Streptococcus pyogenes. The agent also demonstrates both time- and concentration-dependent killing against the pathogens S. pneumoniae and S. aureus. In vitro susceptibility testing demonstrated an MIC50/90 of 0.06/0.12 µg/ml against S. pneumoniae and S. aureus. The SENTRY Antimicrobial Surveillance Program found that at a concentration ≤ 1 µg/ml, lefamulin inhibited 100% S. pneumoniae isolates, 99.8% of S. aureus isolates, and 99.6% of methicillin-resistant S. aureus isolates. It was not affected by resistance to various antibiotic classes such as beta-lactams, fluoroquinolones, or macrolides. Lefamulin is the first pleuromutilin antibiotic approved for the treatment of bacterial infections in humans. Pleuromutilin antibiotics exert their unique mechanism of action which makes them less susceptible to the development of bacterial resistance and low probability of cross-resistance to the other antimicrobial classes. The authors present a critical review of the pharmacology, pharmacokinetics (PK), pharmacodynamics (PD), and data from two pivotal clinical trials of lefamulin in patients with community-acquired bacterial pneumonia (CABP). Lefamulin exhibits both bactericidal and bacteriostatic activity against gram-positive, fastidious gram-negatives, atypical pathogens, and some gram-negative anaerobes. It has shown activity against organisms known to cause sexually transmitted infections, including Mycoplasma genitalium and drug-resistant Neisseria gonorrhoeae. Lefamulin demonstrated no activity against Enterobacteriaceae or Pseudomonas aeruginosa. Pharmacokinetic studies involving lefamulin in acutely ill patients at least 18 years of age with three or more CABP symptoms failed to reveal any clinically significant differences in the PK parameters on the basis of age, sex, race, weight, or renal impairment. Lefamulin 600 mg tablets had a mean oral bioavailability of 25%. Consumption of high-fat meals may slightly reduce the blood level of the drug. In two phase 3 clinical trials, The Lefamulin Evaluation Against Pneumonia 1 and 2 (LEAP 1 and 2) compared the efficacy and safety of lemafulin with moxifloxacin in patients diagnosed with CABP. Lemafulin administered in doses of 600 mg orally or 150 mg intravenously were reported to have comparable efficacy to those of moxifloxacin with or without linezolid in patients with CABP." @default.
• W3127161133 created "2021-02-15" @default.
• W3127161133 creator A5006520705 @default.
• W3127161133 creator A5022308723 @default.
• W3127161133 creator A5033401008 @default.
• W3127161133 creator A5059134248 @default.
• W3127161133 creator A5059949969 @default.
• W3127161133 date "2021-02-02" @default.
• W3127161133 modified "2023-09-23" @default.
• W3127161133 title "Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin" @default.
• W3127161133 cites W2012617927 @default.
• W3127161133 cites W2024451625 @default.
• W3127161133 cites W2088074800 @default.
• W3127161133 cites W2109063989 @default.
• W3127161133 cites W2122415095 @default.
• W3127161133 cites W2122687703 @default.
• W3127161133 cites W2134135813 @default.
• W3127161133 cites W2144202410 @default.
• W3127161133 cites W2173343255 @default.
• W3127161133 cites W2195021565 @default.
• W3127161133 cites W2531025435 @default.
• W3127161133 cites W2551731940 @default.
• W3127161133 cites W2563066297 @default.
• W3127161133 cites W2755089829 @default.
• W3127161133 cites W2799736072 @default.
• W3127161133 cites W2802137144 @default.
• W3127161133 cites W2803396564 @default.
• W3127161133 cites W2884130512 @default.
• W3127161133 cites W2913128833 @default.
• W3127161133 cites W2925580306 @default.
• W3127161133 cites W2927629499 @default.
• W3127161133 cites W2930309673 @default.
• W3127161133 cites W2932357757 @default.
• W3127161133 cites W2973817514 @default.
• W3127161133 cites W2977132187 @default.
• W3127161133 cites W2977322360 @default.
• W3127161133 cites W2986019612 @default.
• W3127161133 cites W2990735299 @default.
• W3127161133 cites W4235175266 @default.
• W3127161133 doi "https://doi.org/10.1007/s40121-020-00378-3" @default.
• W3127161133 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7851634" @default.
• W3127161133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33528794" @default.
• W3127161133 hasPublicationYear "2021" @default.
• W3127161133 type Work @default.
• W3127161133 sameAs 3127161133 @default.
• W3127161133 citedByCount "15" @default.
• W3127161133 countsByYear W31271611332021 @default.
• W3127161133 countsByYear W31271611332022 @default.
• W3127161133 countsByYear W31271611332023 @default.
• W3127161133 crossrefType "journal-article" @default.
• W3127161133 hasAuthorship W3127161133A5006520705 @default.
• W3127161133 hasAuthorship W3127161133A5022308723 @default.
• W3127161133 hasAuthorship W3127161133A5033401008 @default.
• W3127161133 hasAuthorship W3127161133A5059134248 @default.
• W3127161133 hasAuthorship W3127161133A5059949969 @default.
• W3127161133 hasBestOaLocation W31271611331 @default.
• W3127161133 hasConcept C126322002 @default.
• W3127161133 hasConcept C168563851 @default.
• W3127161133 hasConcept C177713679 @default.
• W3127161133 hasConcept C197934379 @default.
• W3127161133 hasConcept C2776102371 @default.
• W3127161133 hasConcept C2776345407 @default.
• W3127161133 hasConcept C2777914695 @default.
• W3127161133 hasConcept C2778836808 @default.
• W3127161133 hasConcept C2778980435 @default.
• W3127161133 hasConcept C2779489039 @default.
• W3127161133 hasConcept C2781414143 @default.
• W3127161133 hasConcept C4937899 @default.
• W3127161133 hasConcept C501593827 @default.
• W3127161133 hasConcept C523546767 @default.
• W3127161133 hasConcept C535046627 @default.
• W3127161133 hasConcept C54355233 @default.
• W3127161133 hasConcept C71924100 @default.
• W3127161133 hasConcept C86803240 @default.
• W3127161133 hasConcept C89423630 @default.
• W3127161133 hasConcept C98274493 @default.
• W3127161133 hasConceptScore W3127161133C126322002 @default.
• W3127161133 hasConceptScore W3127161133C168563851 @default.
• W3127161133 hasConceptScore W3127161133C177713679 @default.
• W3127161133 hasConceptScore W3127161133C197934379 @default.
• W3127161133 hasConceptScore W3127161133C2776102371 @default.
• W3127161133 hasConceptScore W3127161133C2776345407 @default.
• W3127161133 hasConceptScore W3127161133C2777914695 @default.
• W3127161133 hasConceptScore W3127161133C2778836808 @default.
• W3127161133 hasConceptScore W3127161133C2778980435 @default.
• W3127161133 hasConceptScore W3127161133C2779489039 @default.
• W3127161133 hasConceptScore W3127161133C2781414143 @default.
• W3127161133 hasConceptScore W3127161133C4937899 @default.
• W3127161133 hasConceptScore W3127161133C501593827 @default.
• W3127161133 hasConceptScore W3127161133C523546767 @default.
• W3127161133 hasConceptScore W3127161133C535046627 @default.
• W3127161133 hasConceptScore W3127161133C54355233 @default.
• W3127161133 hasConceptScore W3127161133C71924100 @default.
• W3127161133 hasConceptScore W3127161133C86803240 @default.
• W3127161133 hasConceptScore W3127161133C89423630 @default.
• W3127161133 hasConceptScore W3127161133C98274493 @default.
• W3127161133 hasIssue "1" @default.
• W3127161133 hasLocation W31271611331 @default.

• next